Some synonymous and nonsynonymous gyrA mutations in Mycobacterium tuberculosis lead to systematic false-positive fluoroquinolone resistance results with the Hain GenoType MTBDRsl assays

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 4, 2017, Pages

  Ajileye, Adebisi ^a   Alvarez, Nataly ^b,c   Merker, Matthias ^d,e   Walker, Timothy M ^f   Akter, Suriya ^g   Brown, Kerstin ^a   Moradigaravand, Danesh ^h   Schön, Thomas ^i,j   Andres, Sönke ^d   Schleusener, Viola ^d   Omar, Shaheed V ^k   Coll, Francesc ^l   Huang, Hairong ^m   Diel, Roland ⁿ   Ismail, Nazir ^k   Parkhill, Julian ^h   De Jong, Bouke C ^g   Peto, Tim E A ^f   Crook, Derrick W ^f,o   Niemann, Stefan ^d,e   Robledo, Jaime ^b,c   Smith, E Grace ^a   Peacock, Sharon J ^h,l,p   Köser, Claudio U ^p   more..

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b Corporación para Investigaciones Biológicas ^*  (Colombia)

^c UNIVERSIDAD PONTIFICIA BOLIVARIANA   (Colombia)

^d RESEARCH CENTER BORSTEL   (Germany)

^e German Center for Infection Research   (Germany)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^h WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

ⁱ LINKÖPING UNIVERSITY   (Sweden)

^j KALMAR COUNTY HOSPITAL   (Sweden)

^k NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^l LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^m CAPITAL MEDICAL UNIVERSITY   (China)

ⁿ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^o PUBLIC HEALTH ENGLAND   (United Kingdom)

^p UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

Fluoroquinolones; Hain GenoType MTBDRsl; Mycobacterium tuberculosis

Indexed keywords

FLUOROQUINOLONE; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; DNA TOPOISOMERASE (ATP HYDROLYSING); OLIGONUCLEOTIDE PROBE; TUBERCULOSTATIC AGENT;

ARTICLE; ASSAY; BACTERIAL MUTATION; BACTERIAL STRAIN; GENOTYPE; MULTIDRUG RESISTANT TUBERCULOSIS; MUTANT; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; WILD TYPE; BIOASSAY; CHEMISTRY; CLASSIFICATION; DRUG EFFECTS; FALSE POSITIVE RESULT; GENE EXPRESSION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; MULTIDRUG RESISTANCE; MUTATION; OLIGONUCLEOTIDE PROBE; PHYLOGENY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; BIOLOGICAL ASSAY; DNA GYRASE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FALSE POSITIVE REACTIONS; FLUOROQUINOLONES; GENE EXPRESSION; HUMANS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; OLIGONUCLEOTIDE PROBES; PHYLOGENY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85016948589     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02169-16     Document Type: Article

References (49)

1. Tagliani E, Cabibbe AM, Miotto P, Borroni E, Toro JC, Mansjo M, Hoffner S, Hillemann D, Zalutskaya A, Skrahina A, Cirillo DM. 2015. Diagnostic performance of the new version of GenoType MTBDRsl (V2.0) assay for detection of resistance to fluoroquinolones and second line injectable drugs: a multicenter study. J Clin Microbiol 53:2961-2969. https://doi.org/10.1128/JCM.01257-15.
2. Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Zumla A, Migliori GB. 2016. WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. Lancet 387:2486-2487. https://doi.org/10.1016/S0140-6736(16)30729-2.
3. World Health Organization. 2016. The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs. Policy guidance. http://www.who.int/tb/areas-of-work/laboratory/WHOPolicyStatementSLLPA.pdf?ua=1. Accessed 31 July 2016.
4. World Health Organization. 2016. Online annexes (5-8) to WHO policy guidance: the use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs. http://www.who.int/tb/areas-of-work/laboratory/OnlineAnnexes-MTBDRsl.pdf?ua=1. Accessed 2 August 2016.
5. World Health Organization. 2016. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. World Health Organization, Geneva, Switzerland. https://www.ncbi.nlm.nih.gov/books/NBK390455/. Accessed 3 March 2016.
6. Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W. 2010. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol 48:1683-1689. https://doi.org/10.1128/JCM.01947-09.
7. Aubry A, Sougakoff W, Bodzongo P, Delcroix G, Armand S, Millot G, Jarlier V, Courcol R, Lemaître N. 2014. First evaluation of drug-resistant Mycobacterium tuberculosis clinical isolates from Congo revealed misdetection of fluoroquinolone resistance by line probe assay due to a double substitution T80A-A90G in GyrA. PLoS One 9:e95083. https://doi.org/10.1371/journal.pone.0095083.
8. Kaswa MK, Aloni M, Nkuku L, Bakoko B, Lebeke R, Nzita A, Muyembe JJ, de Jong BC, de Rijk P, Verhaegen J, Boelaert M, Ieven M, Van Deun A. 2014. Pseudo-outbreak of pre-extensively drug-resistant (pre-XDR) tuberculosis in Kinshasa: collateral damage caused by false detection of fluoroquinolone resistance by GenoType MTBDRsl. J Clin Microbiol 52:2876-2880. https://doi.org/10.1128/JCM.00398-14.
9. Brossier F, Guindo D, Pham A, Reibel F, Sougakoff W, Veziris N, Aubry A. 2016. Performance of the new version (v2.0) of the GenoType MTBDRsl test for detection of resistance to second-line drugs in multidrug-resistant Mycobacterium tuberculosis complex strains. J Clin Microbiol 54:1573-1580. https://doi.org/10.1128/JCM.00051-16.
10. Aubry A, Veziris N, Cambau E, Truffot-Pernot C, Jarlier V, Fisher LM. 2006. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother 50:104-112. https://doi.org/10.1128/AAC.50.1.104-112.2006.
11. Von Groll A, Martin A, Juréen P, Hoffner S, Vandamme P, Portaels F, Palomino J, da Silva P. 2009. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother 53:4498-4500. https://doi.org/10.1128/AAC.00287-09.
12. Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE. 2012. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One 7:e39754. https://doi.org/10.1371/journal.pone.0039754.
13. Bernard C, Veziris N, Brossier F, Sougakoff W, Jarlier V, Robert J, Aubry A. 2015. Molecular diagnosis of fluoroquinolone resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 59:1519-1524. https://doi.org/10.1128/AAC.04058-14.
14. Walker TM, Kohl TA, Omar SV, Hedge J, Del Ojo Elias C, Bradley P, Iqbal Z, Feuerriegel S, Niehaus KE, Wilson DJ, Clifton DA, Kapatai G, Ip CL, Bowden R, Drobniewski FA, Allix-Beguec C, Gaudin C, Parkhill J, Diel R, Supply P, Crook DW, Smith EG, Walker AS, Ismail N, Niemann S, Peto TE; Modernizing Medical Microbiology (MMM) Informatics Group. 2015. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis 15:1193-1202. https://doi.org/10.1016/S1473-3099(15)00062-6.
15. Pantel A, Petrella S, Veziris N, Matrat S, Bouige A, Ferrand H, Sougakoff W, Mayer C, Aubry A. 2016. Description of compensatory gyrA mutations restoring fluoroquinolone susceptibility in Mycobacterium tuberculosis. J Antimicrob Chemother 71:2428-2431. https://doi.org/10.1093/jac/dkw169.
16. de Jong BC, Antonio M, Gagneux S. 2010. Mycobacterium africanum - review of an important cause of human tuberculosis in West Africa. PLoS Negl Trop Dis 4:e744. https://doi.org/10.1371/journal.pntd.0000744.
17. Feuerriegel S, Köser CU, Niemann S. 2014. Phylogenetic polymorphisms in antibiotic resistance genes of the Mycobacterium tuberculosis complex. J Antimicrob Chemother 69:1205-1210. https://doi.org/10.1093/jac/dkt535.
18. Van Deun A, Aung KJ, Bola V, Lebeke R, Hossain MA, de Rijk WB, Rigouts L, Gumusboga A, Torrea G, de Jong BC. 2013. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 51:2633-2640. https://doi.org/10.1128/JCM.00553-13.
19. Köser CU, Feuerriegel S, Summers DK, Archer JA, Niemann S. 2012. Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance. Antimicrob Agents Chemother 56:6080-6087. https://doi.org/10.1128/AAC.01641-12.
20. Andre E, Goeminne L, Cabibbe A, Beckert P, Kabamba Mukadi B, Mathys V, Gagneux S, Niemann S, Van Ingen J, Cambau E. 2017. Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria. Clin Microbiol Infect 23:167-172. https://doi.org/10.1016/j.cmi.2016.09.006.
21. Alvarez N, Zapata E, Mejia GI, Realpe T, Araque P, Pelaez C, Rouzaud F, Robledo J. 2014. The structural modeling of the interaction between levofloxacin and the Mycobacterium tuberculosis gyrase catalytic site sheds light on the mechanisms of fluoroquinolones resistant tuberculosis in Colombian clinical isolates. Biomed Res Int 2014:367268. https://doi.org/10.1155/2014/367268.
22. Nikam C, Patel R, Sadani M, Ajbani K, Kazi M, Soman R, Shetty A, Georghiou SB, Rodwell TC, Catanzaro A, Rodrigues C. 2016. Redefining MTBDRplus test results: what do indeterminate results actually mean? Int J Tuberc Lung Dis 20:154-159. https://doi.org/10.5588/ijtld.15.0319.
23. Seifert M, Georghiou SB, Catanzaro D, Rodrigues C, Crudu V, Victor TC, Garfein RS, Catanzaro A, Rodwell TC. 2016. MTBDRplus and MTBDRsl assays: the absence of wild-type probe hybridization and implications for the detection of drug-resistant tuberculosis. J Clin Microbiol 54:912-918. https://doi.org/10.1128/JCM.02505-15.
24. Hain Lifescience. 2015. GenoType MTBDRsl VER 2.0. Instructions for use IFU-317A-02. Hain Lifescience, Nehren, Germany.
25. Günther G, Gomez GB, Lange C, Rupert S, van Leth F, TBNET. 2015. Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey. Eur Respir J 45:1081-1088. https://doi.org/10.1183/09031936.00124614.
26. Eilertson B, Maruri F, Blackman A, Herrera M, Samuels DC, Sterling TR. 2014. High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 58:3270-3275. https://doi.org/10.1128/AAC.02066-13.
27. Mitarai S, Kato S, Ogata H, Aono A, Chikamatsu K, Mizuno K, Toyota E, Sejimo A, Suzuki K, Yoshida S, Saito T, Moriya A, Fujita A, Sato S, Matsumoto T, Ano H, Suetake T, Kondo Y, Kirikae T, Mori T. 2012. Comprehensive multicenter evaluation of a new line probe assay kit for identification of Mycobacterium species and detection of drug-resistant Mycobacterium tuberculosis. J Clin Microbiol 50:884-890. https://doi.org/10.1128/JCM.05638-11.
28. Park C, Sung N, Hwang S, Jeon J, Won Y, Min J, Kim CT, Kang H. 2012. Evaluation of reverse hybridization assay for detecting fluoroquinolone and kanamycin resistance in multidrug-resistance Mycobacterium tuberculosis clinical isolates. Tuberc Respir Dis 72:44-49. https://doi.org/10.4046/trd.2012.72.1.44.
29. Ritter C, Lucke K, Sirgel FA, Warren RW, van Helden PD, Böttger EC, Bloemberg GV. 2014. Evaluation of the AID TB resistance line probe assay for rapid detection of genetic alterations associated with drug resistance in Mycobacterium tuberculosis strains. J Clin Microbiol 52:940-946. https://doi.org/10.1128/JCM.02597-13.
30. Lee YS, Kang MR, Jung H, Choi SB, Jo KW, Shim TS. 2015. Performance of REBA MTB-XDR to detect extensively drug-resistant tuberculosis in an intermediate-burden country. J Infect Chemother 21:346-351. https://doi.org/10.1016/j.jiac.2014.12.009.
31. Molina-Moya B, Lacoma A, Prat C, Pimkina E, Diaz J, Garcia-Sierra N, Haba L, Maldonado J, Samper S, Ruiz-Manzano J, Ausina V, Dominguez J. 2015. Diagnostic accuracy study of multiplex PCR for detecting tuberculosis drug resistance. J Infect 71:220-230. https://doi.org/10.1016/j.jinf.2015.03.011.
32. Pang Y, Dong H, Tan Y, Deng Y, Cai X, Jing H, Xia H, Li Q, Ou X, Su B, Li X, Zhang Z, Li J, Zhang J, Huan S, Zhao Y. 2016. Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China. Sci Rep 6:25330. https://doi.org/10.1038/srep25330.
33. Köser CU, Javid B, Liddell K, Ellington MJ, Feuerriegel S, Niemann S, Brown NM, Burman WJ, Abubakar I, Ismail NA, Moore D, Peacock SJ, Török ME. 2015. Drug-resistance mechanisms and tuberculosis drugs. Lancet 385:305-307. https://doi.org/10.1016/S0140-6736(14)62450-8.
34. Chakravorty S, Roh SS, Glass J, Smith LE, Simmons AM, Lund K, Lokhov S, Liu X, Xu P, Zhang G, Via LE, Shen Q, Ruan X, Yuan X, Zhu HZ, Viazovkina E, Shenai S, Rowneki M, Lee JS, Barry CE, III, Gao Q, Persing D, Kwiatkawoski R, Jones M, Gall A, Alland D. 2017. Detection of isoniazid-, fluoroquinolone-, amikacin-, and kanamycin-resistant tuberculosis in an automated, multiplexed 10-color assay suitable for point-of-care use. J Clin Microbiol 55:183-198. https://doi.org/10.1128/JCM.01771-16.
35. Steiner A, Stucki D, Coscolla M, Borrell S, Gagneux S. 2014. KvarQ: targeted and direct variant calling from fastq reads of bacterial genomes. BMC Genomics 15:881. https://doi.org/10.1186/1471-2164-15-881.
36. Bradley P, Gordon NC, Walker TM, Dunn L, Heys S, Huang B, Earle S, Pankhurst LJ, Anson L, de Cesare M, Piazza P, Votintseva AA, Golubchik T, Wilson DJ, Wyllie DH, Diel R, Niemann S, Feuerriegel S, Kohl TA, Ismail N, Omar SV, Smith EG, Buck D, McVean G, Walker AS, Peto TE, Crook DW, Iqbal Z. 2015. Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosis. Nat Commun 6:10063. https://doi.org/10.1038/ncomms10063.
37. Coll F, McNerney R, Preston MD, Guerra-Assuncao JA, Warry A, Hill-Cawthorne G, Mallard K, Nair M, Miranda A, Alves A, Perdigão J, Viveiros M, Portugal I, Hasan Z, Hasan R, Glynn JR, Martin N, Pain A, Clark TG. 2015. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. Genome Med 7:51. https://doi.org/10.1186/s13073-015-0164-0.
38. Feuerriegel S, Schleusener V, Beckert P, Kohl TA, Miotto P, Cirillo DM, Cabibbe AM, Niemann S, Fellenberg K. 2015. PhyResSE: web tool delineating Mycobacterium tuberculosis antibiotic resistance and lineage from whole-genome sequencing data. J Clin Microbiol 53:1908-1914. https://doi.org/10.1128/JCM.00025-15.
39. Iwai H, Kato-Miyazawa M, Kirikae T, Miyoshi-Akiyama T. 2015. CASTB (the comprehensive analysis server for the Mycobacterium tuberculosis complex): a publicly accessible web server for epidemiological analyses, drug-resistance prediction and phylogenetic comparison of clinical isolates. Tuberculosis (Edinb) 95:843-844. https://doi.org/10.1016/j.tube.2015.09.002.
40. Hain Lifescience. 2015. GenoType MTBDRsl VER 1.0. Instructions for use IFU-317-06. Hain Lifescience, Nehren, Germany.
41. Coll F, McNerney R, Guerra-Assuncao JA, Glynn JR, Perdigão J, Viveiros M, Portugal I, Pain A, Martin N, Clark TG. 2014. A robust SNP barcode for typing Mycobacterium tuberculosis complex strains. Nat Commun 5:4812. https://doi.org/10.1038/ncomms5812.
42. Ängeby K, Juréen P, Kahlmeter G, Hoffner SE, Schön T. 2012. Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull World Health Organ 90:693-698. https://doi.org/10.2471/BLT.11.096644.
43. Schön T, Miotto P, Köser CU, Viveiros M, Böttger E, Cambau E. 2016. Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives. Clin Microbiol Infect, in press. https://doi.org/10.1016/j.cmi.2016.10.022.
44. Gao X, Li J, Liu Q, Shen X, Mei J, Gao Q. 2014. Heteroresistance in Mycobacteria tuberculosis is an important factor for the inconsistency between the results of phenotype and genotype drug susceptibility tests. Zhonghua Jie He He Hu Xi Za Zhi 37:260-265.
45. Niemann S, Köser CU, Gagneux S, Plinke C, Homolka S, Bignell H, Carter RJ, Cheetham RK, Cox A, Gormley NA, Kokko-Gonzales P, Murray LJ, Rigatti R, Smith VP, Arends FPM, Cox HS, Smith G, Archer JAC. 2009. Genomic diversity among drug sensitive and multidrug resistant isolates of Mycobacterium tuberculosis with identical DNA fingerprints. PLoS One 4:e7407. https://doi.org/10.1371/journal.pone.0007407.
46. Kiet VS, Lan NT, An DD, Dung NH, Hoa DV, van Vinh Chau N, Chinh NT, Farrar J, Caws M. 2010. Evaluation of the MTBDRsl test for detection of second-line-drug resistance in Mycobacterium tuberculosis. J Clin Microbiol 48:2934-2939. https://doi.org/10.1128/JCM.00201-10.
47. Huang WL, Chi TL, Wu MH, Jou R. 2011. Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of secondline and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 49:2502-2508. https://doi.org/10.1128/JCM.00197-11.
48. Lacoma A, Garcia-Sierra N, Prat C, Maldonado J, Ruiz-Manzano J, Haba L, Gavin P, Samper S, Ausina V, Dominguez J. 2012. GenoType MTBDRsl for molecular detection of second-line-drug and ethambutol resistance in Mycobacterium tuberculosis strains and clinical samples. J Clin Microbiol 50:30-36. https://doi.org/10.1128/JCM.05274-11.
49. Miotto P, Cabibbe AM, Mantegani P, Borroni E, Fattorini L, Tortoli E, Migliori GB, Cirillo DM. 2012. GenoType MTBDRsl performance on clinical samples with diverse genetic background. Eur Respir J 40:690-698. https://doi.org/10.1183/09031936.00164111.